More Amplia Therapeutics Ltd. news
Amplia Therapeutics Ltd.ASX: ATX

First Human Dose in Phase 1 Clinical Trial of AMP945

Oct 8, 2020 at 1:19 AM EDT · Issued by Amplia Therapeutics Ltd.

Filed with ASX · Oct 8, 2020 at 1:19 AM EDT · 1 page · English

On 6ix: 6ix.com/news/first-human-dose-in-phase-1-clinical-trial-of-amp945

Amplia Therapeutics Ltd. on 6ix

Story so far

  • Nucleus Network Appointed to Conduct Phase 1 Clinical TrialJul 23, 2020
  • Entitlement Offer to Fund Phase 1 Clinical TrialJul 1, 2020
  • Preliminary Toxicology Studies Support Phase1 Clinical TrialJun 30, 2020

Earlier from Amplia Therapeutics

  • Amplia Receives Ethics Clearance fo Conduct Phase 1 TrialSep 7, 2020
  • Quarterly Activities and Cashflow Reports - June 2020Jul 26, 2020
  • Nucleus Network Appointed to Conduct Phase 1 Clinical TrialJul 22, 2020
  • Institutional Entitlement Offer CompletedJul 2, 2020
  • Capital Raising - Investor PresentationJul 1, 2020

Later from Amplia Therapeutics

  • Response to ASX Price QueryOct 20, 2020
  • ATX - Sep 2020 Quarter Activities and Cashflow ReportsOct 28, 2020
  • Appendix 4D and Financial Report Half Year Ended 30 Sep 2020Nov 27, 2020
  • Amplia Receives $0.53m R&D Tax IncentiveDec 1, 2020
  • Quarterly Activities and Cashflow Reports - Dec 2020 QtrJan 27, 2021
All Amplia Therapeutics news releases↗

Follow Amplia Therapeutics into a list and get an email when it puts out news.

Follow Amplia Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer